Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2010
03/17/2010CN101674847A Method for stabilizing a protein
03/17/2010CN101674846A Antibodies against erbb3 and uses thereof
03/17/2010CN101674845A Use of an adjuvanted allergy vaccine formulation for parenteral administration
03/17/2010CN101671695A Recombinant vaccinia virus of Tiantan strain with IFN-gamma receptor gene (B8R) deletion and applications thereof
03/17/2010CN101671690A Recombinant expression carrier containing schistosoma japonicum gene and application thereof
03/17/2010CN101671689A Recombinant expression carrier containing schistosoma japonicum gene and application thereof
03/17/2010CN101671654A Monoclonal antibody resisting anaplasma marginale MSP5 protein and application thereof
03/17/2010CN101671393A Angiopoietin-2 specific binding agents
03/17/2010CN101671387A Trichinella spiralis and tumor cell associated antigen protein and preparation method and medical application thereof
03/17/2010CN101671335A Cytotoxins, prodrugs, linkers and stabilizers useful therefor
03/17/2010CN101670119A polynucleotide
03/17/2010CN101670115A Compound of heparanase and heat shock protein, preparation method and applications thereof
03/17/2010CN101670114A Compound of survivin and heat shock protein, preparation method and applications thereof
03/17/2010CN101670105A Humanized antibodies chelated with amylord beta peptide
03/17/2010CN101670104A Oil adjuvant containing panaxoside and preparation method thereof
03/17/2010CN101670103A Compound panax ginseng total saponin and levamisole nano emulsion adjuvant and preparation method thereof
03/17/2010CN101670102A Method for combining poxvirus vector HIV vaccine and adenoviral vector HIV vaccine and application
03/17/2010CN101670101A Attenuated live vaccine
03/17/2010CN101670100A Tolerogenic tumor-cell antigen-loaded dendritic cell, preparation method and application thereof
03/17/2010CN100594038C Human avian influenza special target medicine and preparing method thereof
03/17/2010CN100594037C Complement receptor 2 targeted complement modulators
03/16/2010US7678891 Antibodies that bind CCX-CKR2
03/16/2010US7678890 Compositions and methods of treating disease with FGFR fusion proteins
03/16/2010US7678889 monoclonal antibody for identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and noncancerous disease states in the ovary
03/16/2010US7678822 inhibiting rejection of a transplanted organ, tissue or cell in a recipient mammal; immunosuppressive agent; autoimmune diseases
03/16/2010US7678760 Inhibitors of Memapsin 2 and use thereof
03/16/2010US7678759 Diagnosis and treatment of neuroectodermal tumors
03/16/2010US7678758 For enhancing T cell response to tumour cells
03/16/2010US7678572 Mixing biodegradable devices with T-cells so that one or more agents crosslink with the T-cell surface moieties and deliver a signal to enhance immunostimulatory capabilities;
03/16/2010US7678549 Polyphenol inhibition of nucleoside diphosphate kinase-B activity and cancer metastasis
03/16/2010US7678386 Liposomes coated with selected antibodies that bind to aminophospholipids
03/16/2010US7678379 Mycobacterium tuberculosis epitopes and methods of use thereof
03/16/2010US7678378 Compounds for intracellular delivery of therapeutic moieties to nerve cells
03/16/2010US7678376 Recombinant parainfluenza virus expression systems and vaccines
03/16/2010US7678375 Fusion proteins of Mycobacterium tuberculosis
03/16/2010US7678374 Viral vectors expressing fusion of viral large envelope protein and protein of interest
03/16/2010US7678373 Inhibits fibroblast growth factor (FGF); used to treat a tumor, a cancer, and/or a cell proliferative disorder
03/16/2010US7678372 Tyrosine kinase inhibitors; anticancer agents; genetic engineered protein
03/16/2010US7678371 strategic modifications of non-human donor antibody amino acids (eg. CDR residues); obtains humanized antibody with low immunogenicity
03/16/2010CA2340422C Method for producing yeast expressed hpv types 6 and 16 capsid proteins
03/16/2010CA2296766C Aggrecan degrading metallo proteases
03/16/2010CA2200054C Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
03/16/2010CA2191577C Method for treating and preventing atherosclerosis
03/16/2010CA2160693C Oral drug delivery compositions and methods
03/11/2010WO2010028370A1 Use of ppar gamma modulators to treat cystic liver diseases
03/11/2010WO2010028306A2 Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
03/11/2010WO2010028275A1 METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
03/11/2010WO2010028273A1 Methods for improvement of beta cell function
03/11/2010WO2010028246A2 Novel compositions and adjuvants
03/11/2010WO2010028096A2 Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
03/11/2010WO2010028093A2 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
03/11/2010WO2010028072A2 Avian antibodies specific to influenza virus and technologically simple methods of their manufacture and use
03/11/2010WO2010028066A2 Cd133 epitopes
03/11/2010WO2010027981A1 Multispecific antibodies
03/11/2010WO2010027973A1 Human papillomavirus / li-key hybrids and methods of use
03/11/2010WO2010027965A1 Compositions and methods for decreasing type iii deiodinase activity to modulate adiposity and blood glucose levels
03/11/2010WO2010027818A2 Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
03/11/2010WO2010027797A1 T-cell receptor antibodies and methods of use thereof
03/11/2010WO2010027743A1 Pharmaceutical compositions and methods for the treatment of dry eye
03/11/2010WO2010027736A2 Antimicrobial protein compositions and production therefor from marine bacteria
03/11/2010WO2010027729A2 Gonococcal vaccines
03/11/2010WO2010027501A2 Anti-lipid antibodies
03/11/2010WO2010027499A2 Methods, compositions and vaccines relating to neisseria meningitidis antibodies
03/11/2010WO2010027488A2 Monoclonal antibodies
03/11/2010WO2010027473A2 Immunogenic escherichia coli heat stable enterotoxin
03/11/2010WO2010027458A2 Pdk inhibitor compounds and methods of use thereof
03/11/2010WO2010027423A2 Compositions of pd-1 antagonists and methods of use
03/11/2010WO2010027370A1 Compositions and methods for the treatment of solid tumor cancers
03/11/2010WO2010026638A1 Hyperthermic therapy kit for malignant tumor comprising anti-regulatory-t-cell antibody and magnetic microparticle, and hyperthermic therapy using the kit
03/11/2010WO2010026602A2 Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis
03/11/2010WO2010026432A1 Method for purifying protein complexes
03/11/2010WO2010026385A1 Outer membrane vesicle prime - protein boost vaccine
03/11/2010WO2010026291A1 Materials and methods for inhibiting cancer cell invasion related to fgfr4
03/11/2010WO2010026239A1 Composition comprising chitosan for ocular administration of vaccine(s) to avians
03/11/2010WO2010025964A1 Vaccine comprising protein nmbo964 from meisseria meningitidis
03/11/2010WO2010025542A1 Lps based vaccines
03/11/2010WO2010025541A1 Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen
03/11/2010WO2010006168A3 Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
03/11/2010WO2010004438A3 Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
03/11/2010WO2010002989A3 Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides
03/11/2010WO2009158529A8 Lyophilization cycle robustness strategy
03/11/2010WO2009155484A3 Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
03/11/2010WO2009155476A3 Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains
03/11/2010WO2009150429A3 Foot- and mouth disease marker vaccine
03/11/2010WO2009143483A9 PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
03/11/2010WO2009143472A3 Method of generating single vl domain antibodies in transgenic animals
03/11/2010WO2009141736A3 Inhibition of emmprin to treat multiple sclerosis
03/11/2010WO2009128949A3 Compositions of dengue viral proteins and methods of use
03/11/2010WO2009095646A3 Peptides from factor viii
03/11/2010WO2009082593A3 Dendritic cell vaccine compositions and uses of same
03/11/2010WO2008157409A8 Lyophilized immunoglobulin formulations and methods of preparation
03/11/2010WO2008118470A3 Acute transmitted hiv envelope signatures
03/11/2010US20100063260 Whitefly Ecdysone Receptor Antibody
03/11/2010US20100063250 Truncated tau proteins
03/11/2010US20100062489 Duck embryonic derived stem cell lines for the production of viral vaccines
03/11/2010US20100062071 Particle Formulations and Uses Thereof
03/11/2010US20100062028 Vaccines for malaria
03/11/2010US20100062027 Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
03/11/2010US20100062026 Poly tlr antagonist
03/11/2010US20100062025 Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine
1 ... 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 ... 1823